Kalvista Pharmaceuticals Inc (KALV) USD0.001
$0.61
(5.55%)
- Add to watchlist
- This stock can be held in a
$0.61
(5.55%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.61
(5.55%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Contact details
Important dates
General stock information
- Short code:
- KALV
- ISIN:
- US4834971032
- Market cap:
- $485.74 million
- Shares in issue:
- 43.22 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.